Trending

Crohn’s disease

AbbVie/Allergan merger cleared in EU with brazikumab sell-off

AbbVie/Allergan merger cleared in EU with brazikumab sell-off

AbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of

X

AbbVie/Allergan merger cleared in EU with brazikumab sell-off

https://pharmaphorum.com/news/abbvie-allergan-merger-cleared-in-eu-with-brazikumab-sell-off/

AZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie merger

AZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie merger

Allergan is selling rights to its Crohn’s disease drug brazikumab back to AstraZeneca in a move to satisfy

X

AZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie merger

https://pharmaphorum.com/news/az-buys-back-rights-to-crohns-candidate-from-allergan-ahead-of-abbvie-merger/

Allergan says it will shed two drugs as AbbVie takeover looms

Allergan says it will shed two drugs as AbbVie takeover looms

Allergan has confirmed that it will divest experimental inflammatory bowel disease therapy brazikumab and marketed drug Zenpep ahead

X

Allergan says it will shed two drugs as AbbVie takeover looms

https://pharmaphorum.com/news/allergan-says-it-will-shed-two-drugs-as-abbvie-takeover-looms/

Abivax sets its course on colitis and Crohn’s

Abivax sets its course on colitis and Crohn’s

French biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464

X

Abivax sets its course on colitis and Crohn’s

https://pharmaphorum.com/news/abivax-scolitis-crohns/

Takeda finalises buyout of TiGenix

Takeda finalises buyout of TiGenix

Japanese pharma giant Takeda has completed its buyout of TiGenix. Takeda’s main R&D focus is in oncology, gastroenterology

X

Takeda finalises buyout of TiGenix

https://pharmaphorum.com/news/japanese-takeda-finalises-tigenix-boyout/

Pioneering Crohn’s antibiotic treatment meets early target

Pioneering Crohn’s antibiotic treatment meets early target

A drug targeted at treating Crohn’s disease has shown promise following positive results in a phase 3 trial.

X

Pioneering Crohn’s antibiotic treatment meets early target

https://pharmaphorum.com/news/pioneering-crohns-antibiotic-treatment-meets-early-target/

First ever ‘off the shelf’ stem cell therapy nears European approval

First ever ‘off the shelf’ stem cell therapy nears European approval

Alofisel recommended for complex perianal fistulas in Crohn’s disease

X

First ever ‘off the shelf’ stem cell therapy nears European approval

https://pharmaphorum.com/news/tigenixtakeda-stem-cell-therapy-backed-eu-regulators/

Janssen inks potential $1bn deal for IBD drug

Janssen has swooped to buy rights to an early-stage oral inflammatory bowel disease drug from Protagonist Therapeutics in

X

Janssen inks potential $1bn deal for IBD drug

https://pharmaphorum.com/news/janssen-inks-potential-1bn-deal-ibd-drug/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com